{"organizations": [], "uuid": "20664bddeea233fe532d55e399e20c1f74d3c7bf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-endocyte-announces-phase-3-vision/brief-endocyte-announces-phase-3-vision-trialprovides-update-on-corporate-strategy-and-reports-q4-and-2017-financial-results-idUSASB0C7EH", "country": "US", "domain_rank": 408, "title": "BRIEF-Endocyte Announces Phase 3 Vision Trial,Provides Update On Corporate Strategy And Reports Q4 And 2017 Financial Results", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-26T15:21:00.000+02:00", "replies_count": 0, "uuid": "20664bddeea233fe532d55e399e20c1f74d3c7bf"}, "author": "", "url": "https://www.reuters.com/article/brief-endocyte-announces-phase-3-vision/brief-endocyte-announces-phase-3-vision-trialprovides-update-on-corporate-strategy-and-reports-q4-and-2017-financial-results-idUSASB0C7EH", "ord_in_thread": 0, "title": "BRIEF-Endocyte Announces Phase 3 Vision Trial,Provides Update On Corporate Strategy And Reports Q4 And 2017 Financial Results", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "provides update on corp", "sentiment": "negative"}, {"name": "vision trial", "sentiment": "negative"}, {"name": "endocyte inc", "sentiment": "none"}, {"name": "itm", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 22 PM / Updated 6 minutes ago BRIEF-Endocyte Announces Phase 3 Vision Trial,Provides Update On Corporate Strategy And Reports Q4 And 2017 Financial Results Reuters Staff 1 Min Read Feb 26 (Reuters) - Endocyte Inc: * ENDOCYTE ANNOUNCES PHASE 3 VISION TRIAL AND PROVIDES UPDATE ON CORPORATE STRATEGY AND REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS * Q4 LOSS PER SHARE $0.18 * ANNOUNCED AGREEMENT FOR CLINICAL SUPPLY OF NO-CARRIER-ADDED LUTETIUM WITH ITM * CAR T-CELL THERAPY EXPECTED TO BEGIN CLINICAL DEVELOPMENT IN Q4 OF 2018 * ‍ ENROLLMENT OF VISION TRIAL IS EXPECTED TO BEGIN IN Q2 OF 2018 AND IS EXPECTED TO BE COMPLETED IN 18-24 MONTHS​ * CASH, CASH EQUIVALENTS & INVESTMENTS WERE $97.5 MILLION AT DEC. 31, 2017, VERSUS $103.1 MILLION AT SEPT. 30, 2017 * ‍ FIRST INTERIM ASSESSMENT OF OS FOR VISION TRIAL COULD OCCUR AS EARLY AS SECOND HALF OF 2019​ * ANTICIPATES ITS CASH, CASH EQUIVALENTS AND INVESTMENTS BALANCE AT END OF 2018 TO EXCEED $50 MILLION * HAS SUFFICIENT CASH TO FUND ITS ACTIVITIES INTO SECOND HALF OF 2019 THROUGH MANY IMPORTANT MILESTONES  ", "external_links": [], "published": "2018-02-26T15:21:00.000+02:00", "crawled": "2018-02-26T15:39:41.010+02:00", "highlightTitle": ""}